Robotic pancreaticoduodenectomy (RPD) offers similar or superior outcomes compared to open approaches for pancreatic ductal adenocarcinoma (PDAC) treatment. RPD shows reduced blood loss, lower post-operative pain, and shorter hospital stays. Despite similar operative times, RPD yields better oncological results, including margin status and survival rates. With increasing experience, RPD is poised to become the preferred minimally-invasive option for PDAC surgery.